SCHEDULE: Adage Capital Reports 1.88% Stake in BridgeBio Oncology
Beneficial Ownership Report (Amendment)
Adage Capital Management and its principals have filed an amended Schedule 13G, reporting a 1.88% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported beneficial ownership of 1,487,621 shares of BridgeBio Oncology Therapeutics, Inc. Common Stock.
- This ownership represents 1.88% of the company's outstanding Common Stock.
- The percentage is calculated based on an aggregate of 79,196,710 shares of Common Stock outstanding as of August 11, 2025.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership report (Schedule 13G Amendment No. 1) and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It is a factual disclosure of an existing ownership stake.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date as of which 79,196,710 shares of Common Stock were reported outstanding for percentage calculation. |
| 2025-09-10 | Date of filing of the Company's Prospectus pursuant to Rule 424(b)(3) with the SEC. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-13 | Date of signing of the Schedule 13G Amendment No. 1. |
Keywords
BridgeBio Oncology Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, Equity Stake, Biotechnology, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.